睿知中国疾病研究地图
候选清单0

即将招募肝细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由南方医科大学南方医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方南方医科大学南方医院Nanfang Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07565415,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Child-Pugh score ≤ 7

    入选标准第 3 条

  3. At least one measurable lesion per RECIST 1.1 criteria; lesions without prior radiotherapy, cryotherapy or other local treatment

    入选标准第 4 条

    Fertile male and female patients agree to effective contraception from screening to 120 days after last study drug

    入选标准第 21 条

    Unresolved adverse toxicities from prior antitumor therapy not recovered to ≤ Grade 1 (CTCAE v5.0), excluding alopecia

    排除标准第 5 条

  4. ECOG performance status 0 or 1

    入选标准第 11 条

  5. Hematology: ANC ≥ 1.5×10⁹/L, Hb ≥ 80 g/L, PLT ≥ 50×10⁹/L

    入选标准第 14 条

    Liver function: TBIL ≤ 1.5×ULN, AST/ALT ≤ 5.0×ULN, ALB ≥ 28 g/L

    入选标准第 15 条

    Coagulation function: INR, PT or aPTT ≤ 1.5×ULN

    入选标准第 16 条

    Renal function: SCr ≤ 1.5×ULN or creatinine clearance ≥ 60 mL/min

    入选标准第 17 条

  6. History of other malignancies within 5 years before randomization, except curable low-risk tumors

    排除标准第 4 条

    Positive HIV infection

    排除标准第 8 条

  7. Females of childbearing potential with negative pregnancy test within 3 days before first dosing

    入选标准第 20 条

    Pregnant, breastfeeding females or those planning pregnancy during the study

    排除标准第 6 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07565415,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients with unresectable primary hepatocellular carcinoma (HCC) confirmed by imaging or histopathology
  2. No previous receipt of immunotherapy and/or targeted drug therapy
  3. Child-Pugh score ≤ 7
  4. At least one measurable lesion per RECIST 1.1 criteria; lesions without prior radiotherapy, cryotherapy or other local treatment
  5. Single intrahepatic lesion < 10 cm, or fewer than 10 intrahepatic lesions with tumor burden < 50%
  6. Meet precachexia criteria: non-volitional weight loss ≤ 5% in 6 months, plus systemic inflammation (CRP > 5 mg/L) or decreased appetite (FAACT-A/CS-12 score ≤ 37 points)
  7. Meet cachexia criteria: accompanied by decreased appetite or systemic inflammation, with either non-volitional weight loss > 5% in 6 months or BMI < 18.5 kg/m² plus weight loss > 2%
  8. Voluntarily participate and sign informed consent
  9. Age ≥ 18 years, male or female
  10. Able to swallow tablets normally
  11. ECOG performance status 0 or 1
  12. Life expectancy ≥ 12 weeks
  13. Adequate major organ function without blood products or colony-stimulating factors within 14 days
  14. Hematology: ANC ≥ 1.5×10⁹/L, Hb ≥ 80 g/L, PLT ≥ 50×10⁹/L
  15. Liver function: TBIL ≤ 1.5×ULN, AST/ALT ≤ 5.0×ULN, ALB ≥ 28 g/L
  16. Coagulation function: INR, PT or aPTT ≤ 1.5×ULN
  17. Renal function: SCr ≤ 1.5×ULN or creatinine clearance ≥ 60 mL/min
  18. Urine protein ≤ 1+ or 24-hour urine protein < 1.0 g
  19. Cardiac function: LVEF ≥ 50%
  20. Females of childbearing potential with negative pregnancy test within 3 days before first dosing
  21. Fertile male and female patients agree to effective contraception from screening to 120 days after last study drug
  22. HBV/HCV infected patients receive stable antiviral therapy without drug interaction

排除标准:Exclusion Criteria:

  1. Active or untreated CNS metastases; inadequately controlled metastatic brain or leptomeningeal disease
  2. Uncontrolled tumor-related pain
  3. Thromboembolic disease, ascites or lower limb edema within 6 months
  4. History of other malignancies within 5 years before randomization, except curable low-risk tumors
  5. Unresolved adverse toxicities from prior antitumor therapy not recovered to ≤ Grade 1 (CTCAE v5.0), excluding alopecia
  6. Pregnant, breastfeeding females or those planning pregnancy during the study
  7. Any unstable medical, psychiatric or social condition that may interfere with study participation
  8. Positive HIV infection
  9. Major surgery within 28 days prior to randomization
  10. Severe cardiovascular disease, myocardial infarction, unstable arrhythmia, angina or cerebrovascular events
  11. Severe systemic infection within 4 weeks before dosing or active infection requiring systemic anti-infective treatment
  12. Impaired gastrointestinal absorption, long-term tube feeding, parenteral nutrition or eating disorders
  13. Concomitant use of other appetite-enhancing or weight-stimulating agents
  14. Cushing's syndrome, adrenal or pituitary insufficiency, poorly controlled diabetes
  15. Uncontrolled hypertension despite oral antihypertensive treatment
  16. Esophagogastric varices, severe ulcers, gastrointestinal bleeding, obstruction, perforation or fistula within 6 months
  17. Known hypersensitivity to any component of the investigational product
  18. Any other condition considered inappropriate for enrollment by the investigator.

引自 ClinicalTrials.gov, NCT07565415, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07565415,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07565415